Evidence map›Paper›PMID 18802462›Full record

ArticlePLoS genetics2008

Screening and replication using the same data set: testing strategies for family-based studies in which all probands are affected.

Amy Murphy, Scott T Weiss, Christoph Lange

Abstract read
In one paragraph

Article in PLoS genetics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Genetics of food allergy.Current opinion in pediatrics · 2009
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amy MurphyChanning Laboratory, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Scott T Weiss
Christoph Lange

Funding

THE PHARMACOGENETICS OF ASTHMA TREATMENTU01HL065899 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G, WEISS, SCOTT T · 2000 to 2014
$38.5M
SYSTEMS APPROACHES TO THE EPIDEMIOLOGY, GENETICS AND GENOMICS OF LUNG DISEASEST32HL007427 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DAWN L DEMEO, Edwin K Silverman · 1985 to 2026
$13.6M
Statistical GeneticsP01HL083069 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI WEISS, SCOTT T · 2007 to 2011
$12.2M
Genetics and Gene Expression Profiling in AsthmaR01HL086601 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI RABY, BENJAMIN ALEXANDER · 2007 to 2015
$6.8M
CAMP Continuation Study/Phase 3U01HL075419 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FUHLBRIGGE, ANNE L · 2003 to 2010
$2.0M
NHLBI NIH HHS P01 HL083069NHLBI NIH HHS R01 HL086601NHLBI NIH HHS T32 HL007427NHLBI NIH HHS T32 HL07427NHLBI NIH HHS U01 HL065899NHLBI NIH HHS U01 HL075419NHLBI NIH HHS U01 HL65899PHS HHS R01 59532
6 · The paper itself

Abstract

For genome-wide association studies in family-based designs, we propose a powerful two-stage testing strategy that can be applied in situations in which parent-offspring trio data are available and all offspring are affected with the trait or disease under study. In the first step of the testing strategy, we construct estimators of genetic effect size in the completely ascertained sample of affected offspring and their parents that are statistically independent of the family-based association/transmission disequilibrium tests (FBATs/TDTs) that are calculated in the second step of the testing strategy. For each marker, the genetic effect is estimated (without requiring an estimate of the SNP allele frequency) and the conditional power of the corresponding FBAT/TDT is computed. Based on the power estimates, a weighted Bonferroni procedure assigns an individually adjusted significance level to each SNP. In the second stage, the SNPs are tested with the FBAT/TDT statistic at the individually adjusted significance levels. Using simulation studies for scenarios with up to 1,000,000 SNPs, varying allele frequencies and genetic effect sizes, the power of the strategy is compared with standard methodology (e.g., FBATs/TDTs with Bonferroni correction). In all considered situations, the proposed testing strategy demonstrates substantial power increases over the standard approach, even when the true genetic model is unknown and must be selected based on the conditional power estimates. The practical relevance of our methodology is illustrated by an application to a genome-wide association study for childhood asthma, in which we detect two markers meeting genome-wide significance that would not have been detected using standard methodology.

Indexed as

Genome, HumanAsthmaChildComputer SimulationFamilyFemaleGenetic MarkersGenetics, MedicalGenetics, PopulationGenetic TestingHumansMaleModels, GeneticModels, StatisticalPedigreePolymorphism, Single NucleotideGenetic Markers

Identifiers

PMID18802462
PMCPMC2529406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.